Nanomedicine: Nanotechnology, Biology and Medicine
Volume 8, Issue 2 , Pages 204-211 , February 2012

Gold-doxorubicin nanoconjugates for overcoming multidrug resistance

  • Yan-Juan Gu, PhD

      Affiliations

    • Department of Biology and Chemistry, The City University of Hong Kong, Kowloon, Hong Kong, China
    • These two authors contributed equally to this work.
    • ,
  • Jinping Cheng, PhD

      Affiliations

    • Department of Biology and Chemistry, The City University of Hong Kong, Kowloon, Hong Kong, China
    • These two authors contributed equally to this work.
    • ,
  • Cornelia Wing-Yin Man, PhD

      Affiliations

    • Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, China
    • ,
  • Wing-Tak Wong, PhD

      Affiliations

    • Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, China
    • ,
  • Shuk Han Cheng, PhD

      Affiliations

    • Department of Biology and Chemistry, The City University of Hong Kong, Kowloon, Hong Kong, China
    • Corresponding Author InformationCorresponding author.

Received 28 September 2010 ,Accepted 5 June 2011.

References 

  1. Cucco C, Calabretta B. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by MDR1 antisense oligonucleotides. Cancer Res. 1996;56:4332–4337
  2. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci. 2008;65:3145–3167
  3. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics. 2003;4:397–410
  4. Cole SP, Deeley RG. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays. 1998;20:931–940
  5. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP(ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005;204:216–237
  6. Pakunlu RI, Wang Y, Tsao W, Pozharov V, Cook TJ, Minko T. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system. Cancer Res. 2004;64:6214–6224
  7. Yang X, Deng W, Fu L, Blanco E, Gao J, Quan D, et al. Folate-functionalized polymeric micelles for tumor targeted delivery of a potent multidrug-resistance modulator FG020326. J Biomed Mater Res A. 2008;86A:48–60
  8. Chavanpatil MD, Khdair A, Gerard B, Bachmeier C, Miller DW, Shekhar MPV, et al. Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. Mol Pharm. 2007;4:730–738
  9. Sadava D, Coleman A, Kane SE. Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. J Liposome Res. 2002;12:301–309
  10. Lee S, Cha EJ, Park K, Lee SY, Hong JK, Sun IC, et al. A near-infrared-fluorescence-quenched gold-nanoparticle imaging probe for in vivo drug screening and protease activity determination. Angew Chem Int Ed Engl. 2008;47:1–5
  11. Yu AM, Liang ZJ, Cho JH, Caruso F. Nanostructured electrochemical sensor based on dense gold nanoparticle films. Nano Lett. 2003;3:1203–1207
  12. Chen YH, Tsai CY, Huang PY, Chang MY, Cheng PC, Chou CH, et al. Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model. Mol Pharm. 2007;4:713–722
  13. Podsiadlo P, Sinani VA, Bahng JH, Kam NWS, Lee J, Kotov NA. Gold nanoparticles enhance the anti-leukemia action of a 6-mercaptopurine chemotherapeutic agent. Langmuir. 2008;24:568–574
  14. Frederick CA, Williams LD, Ughetto G, van der Marel GA, van Boom JH, Rich A, et al. Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry. 1990;29:2538–2549
  15. Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, et al. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol. 2004;31:53–90
  16. Mamidi RNVS, Weng S, Stellar S, Wang C, Yu N, Huang T, et al. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?. Cancer Chemother Pharmacol. 2010;66:1173–1184
  17. Batrakova EV, Kelly DL, Li S, Li Y, Yang Z, Xiao L, et al. Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85. Mol Pharm. 2006;3:113–123
  18. Marchi N, Hallene KL, Kight KM, Cucullo L, Moddel G, Bingaman W, et al. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. Biomed Central Med. 2004;2:37–47
  19. Lee ES, Na K, Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release. 2005;103:405–418
  20. Greco F, Vicent MJ, Gee S, Gee AT, Jones J, Nicholson RI, et al. Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells. J Control Release. 2007;117:28–39
  21. Tang N, Du G, Wang N, Liu C, Hang H, Liang W. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst. 2007;99:1004–1015
  22. Theodossiou TA, Galanou MC, Paleos CM. Novel amiodarone-doxorubicin cocktail liposomes enhance doxorubicin retention and cytotoxicity in DU145 human prostate carcinoma cells. J Med Chem. 2008;51:6067–6074
  23. Laginha KM, Verwoert S, Charrois GJR, Allen TM. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res. 2005;11:6944–6949
  24. Alakhov VY, Moskaleva EY, Batrakova EV, Kabanov AV. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug Chem. 1996;7:209–216
  25. Yoo HS, Lee EA, Park TG. Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages. J Control Release. 2002;82:17–27
  26. Gu YJ, Cheng J, Lin CC, Lam YW, Cheng SH, Wong WT. Nuclear penetration of surface functionalized gold nanoparticles. Toxicol Appl Pharmacol. 2009;237:196–204
  27. Wang C, Zhang JX, Shen XL, Wan ECK, Tse KWN, Fong WF. Reversal of P-glycoprotein-mediated multidrug resistance by alisol B 23-acetate. Biochem Pharmacol. 2004;68:843–855
  28. Fong WF, Shen XL, Globisch C, Wiese M, Chen GY, Zhu GY, et al. Methoxylation of 3′,4′-aromatic side chains improves P-glycoprotein inhibitory and multidrug resistance reversal activities of 7,8-pyranocoumarin against cancer cells. Bioorg Med Chem. 2008;16:3694–3703
  29. Kam NWS, Liu Z, Dai H. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J Am Chem Soc. 2005;127:12492–12493
  30. Giri S, Trewyn BG, Stellmaker MP, Lin VSY. Stimuli-responsive controlled-release delivery system based on mesoporous silica nanorods capped with magnetic nanoparticles. Angew Chem Int Ed Engl. 2005;44:5038–5044
  31. Zhou X, Chang YC, Oyama T, McGuire MJ, Brown KC. Cell-specific delivery of a chemotherapeutic to lung cancer cells. J Am Chem Soc. 2004;126:15656–15657
  32. Albert BJ, McPherson PA, O'Brien K, Czaicki NL, DeStefino V, Osman S, et al. Meayamycin inhibits pre–messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells. Mol. Cancer Ther. 2009;8:2308–2318
  33. Prabaharan M, Grailer JJ, Pilla S, Steeber DA, Gong S. Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery. Biomaterials. 2009;30:6065–6075
  34. Yoo HS, Park TG. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control Release. 2004;100:247–256
  35. Li J, Wang X, Wang C, Chen B, Dai Y, Zhang R, et al. The enhancement effect of gold nanoparticles in drug delivery and as biomarkers of drug-resistant cancer cells. ChemMedChem. 2007;2:374–378
  36. Aryal S, Grailer JJ, Pilla S, Steeber DA, Gong S. Doxorubicin conjugated gold nanoparticles as water-soluble and pH-responsive anticancer drug nanocarriers. J Mater Chem. 2009;19:7879–7884
  37. Satyam A. Design and synthesis of releasable folate-drug conjugates using a novel heterobifunctional disulfide-containing linker. Bioorg Med Chem Lett. 2008;18:3196–3199
  38. Ellis CN, Ellis MB, Blakemore WS. Effect of adriamycin on heart mitochondrial DNA. Biochem J. 1987;245:309–312
  39. Lampidis TJ, Hasin Y, Weiss MJ, Chen LB. Selective killing of carcinoma cells “in vitro” by lipophilic-cationic compounds: a cellular basis. Biomed Pharmacother. 1985;39:220–226
  40. Gupta R, Guralnik G, Kilcup GW, Patel A, Sharpe SR. Clear evidence for a first-order chiral transition in QCD. Phys Rev Lett. 1986;57:2621–2624
  41. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol. 2005;391:71–97
  42. Koktorovova S, Souto EB. Nanostructured lipid carrier-based hydrogel formulation for drug delivery: a comprehensive review. Expert Opin Drug Del. 2009;6:165–167

 This study was supported by a grant from the Research Grants Council of the Hong Kong SAR, China (Project No. CityU 160108) and a Research Scholarship to Y-J. Gu from the CityU Research Scholarship Enhancement Scheme.

PII: S1549-9634(11)00258-9

doi: 10.1016/j.nano.2011.06.005

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 8, Issue 2 , Pages 204-211 , February 2012

Article Tools

* Image Usage & Resolution